MedPath

Quralis Corporation

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants

Phase 1
Active, not recruiting
Conditions
Healthy Volunteers
Interventions
First Posted Date
2025-03-14
Last Posted Date
2025-05-04
Lead Sponsor
QurAlis Corporation
Target Recruit Count
25
Registration Number
NCT06877624
Locations
πŸ‡³πŸ‡±

ICON plc. Van Swietenlaan 6, Groningen, Netherlands

A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS

Phase 1
Recruiting
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Other: Placebo
First Posted Date
2024-12-03
Last Posted Date
2025-03-28
Lead Sponsor
QurAlis Corporation
Target Recruit Count
12
Registration Number
NCT06714396
Locations
πŸ‡³πŸ‡±

Universitair Medisch Centrum Utrecht, Utrecht, Netherlands

A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: QRL-101 Dose A
Drug: QRL-101 Dose B
Drug: Placebo
First Posted Date
2024-11-08
Last Posted Date
2025-03-25
Lead Sponsor
QurAlis Corporation
Target Recruit Count
24
Registration Number
NCT06681441
Locations
πŸ‡³πŸ‡±

Centre for Human Drug Research, Leiden, Netherlands

A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2024-08-01
Last Posted Date
2025-02-14
Lead Sponsor
QurAlis Corporation
Target Recruit Count
60
Registration Number
NCT06532396
Locations
πŸ‡³πŸ‡±

ICON plc. Van Swietenlaan 6, Groningen, Netherlands

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Other: Placebo
First Posted Date
2022-12-29
Last Posted Date
2024-04-15
Lead Sponsor
QurAlis Corporation
Target Recruit Count
88
Registration Number
NCT05667779
Locations
πŸ‡³πŸ‡±

ICON plc. Van Swietenlaan 6, Groningen, Netherlands

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

Phase 1
Recruiting
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Multiple ascending doses of QRL-201
Drug: Placebo
Drug: Multiple ascending doses of Placebo
First Posted Date
2022-12-01
Last Posted Date
2025-04-08
Lead Sponsor
QurAlis Corporation
Target Recruit Count
64
Registration Number
NCT05633459
Locations
πŸ‡§πŸ‡ͺ

Universitaire Ziekenhuizen Leuven (UZ Leuven), Leuven, Belgium

πŸ‡¨πŸ‡¦

University of Calgary, Calgary, Alberta, Canada

πŸ‡¨πŸ‡¦

University of Alberta, Edmonton, Alberta, Canada

and more 11 locations
Β© Copyright 2025. All Rights Reserved by MedPath